Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix(Hospital Clínic de Barcelona), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Masatoshi Makuuchi(Nagano Children's Hospital), Han Chu Lee(Asan Medical Center), Masatoshi Kudo(Kindai University), Kwang‐Hyub Han(Yonsei University), Tianqiang Song(Tianjin Medical University Cancer Institute and Hospital), Marie‐Aude Le Berre(Bayer (France)), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Jiamei Yang(Jilin University), Tadatoshi Takayama(Nihon University), Gar-Yang Chau(Taipei Veterans General Hospital), Jianqiang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Gerold Meinhardt(Daiichi Sankyo (United States)), Fabrício Henrique Pereira De Souza, Ronnie T.P. Poon(Queen Mary Hospital), Luigi Bolondi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Won Young Tak(Kyungpook National University Hospital), Sasan Roayaie(White Plains Hospital), Kwan Sik Lee(Gangnam Severance Hospital)
Cited by 1,116
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k